Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial
Sapropterin dihydrochloride, a synthetic formulation of BH4, the cofactor for phenylalanine hydroxylase (PAH, EC 1.14.16.1), was initially approved in Europe only for patients ≥4 years with BH4-responsive phenylketonuria. The aim of the SPARK (Safety Paediatric efficAcy phaRmacokinetic with Kuvan®)...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
9 March 2017
|
| In: |
Orphanet journal of rare diseases
Year: 2017, Jahrgang: 12, Pages: 1-11 |
| ISSN: | 1750-1172 |
| DOI: | 10.1186/s13023-017-0600-x |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s13023-017-0600-x Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13023-017-0600-x 
|
| Verfasserangaben: | Ania C. Muntau, Alberto Burlina, François Eyskens, Peter Freisinger, Corinne De Laet, Vincenzo Leuzzi, Frank Rutsch, H. Serap Sivri, Suresh Vijay, Milva Orquidea Bal, Gwendolyn Gramer, Renata Pazdírková, Maureen Cleary, Amelie S. Lotz-Havla, Alain Munafo, Diane R. Mould, Flavie Moreau-Stucker and Daniela Rogoff |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580453279 | ||
| 003 | DE-627 | ||
| 005 | 20250206100057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180828s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13023-017-0600-x |2 doi | |
| 035 | |a (DE-627)1580453279 | ||
| 035 | |a (DE-576)510453279 | ||
| 035 | |a (DE-599)BSZ510453279 | ||
| 035 | |a (OCoLC)1341017746 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Muntau, Ania |d 1965- |e VerfasserIn |0 (DE-588)128520094 |0 (DE-627)37420294X |0 (DE-576)170651339 |4 aut | |
| 245 | 1 | 0 | |a Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years |b results from the SPARK open-label, multicentre, randomized phase IIIb trial |c Ania C. Muntau, Alberto Burlina, François Eyskens, Peter Freisinger, Corinne De Laet, Vincenzo Leuzzi, Frank Rutsch, H. Serap Sivri, Suresh Vijay, Milva Orquidea Bal, Gwendolyn Gramer, Renata Pazdírková, Maureen Cleary, Amelie S. Lotz-Havla, Alain Munafo, Diane R. Mould, Flavie Moreau-Stucker and Daniela Rogoff |
| 264 | 1 | |c 9 March 2017 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.08.2018 | ||
| 520 | |a Sapropterin dihydrochloride, a synthetic formulation of BH4, the cofactor for phenylalanine hydroxylase (PAH, EC 1.14.16.1), was initially approved in Europe only for patients ≥4 years with BH4-responsive phenylketonuria. The aim of the SPARK (Safety Paediatric efficAcy phaRmacokinetic with Kuvan®) trial was to assess the efficacy (improvement in daily phenylalanine tolerance, neuromotor development and growth parameters), safety and pharmacokinetics of sapropterin dihydrochloride in children <4 years. | ||
| 700 | 1 | |a Gramer, Gwendolyn |d 1979- |e VerfasserIn |0 (DE-588)132278626 |0 (DE-627)520401697 |0 (DE-576)299048179 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orphanet journal of rare diseases |d London : BioMed Central, 2006 |g 12(2017), Artikel-ID 47, Seite 1-11 |h Online-Ressource |w (DE-627)50900637X |w (DE-600)2225857-7 |w (DE-576)260614424 |x 1750-1172 |7 nnas |a Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years results from the SPARK open-label, multicentre, randomized phase IIIb trial |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g elocationid:47 |g pages:1-11 |g extent:11 |a Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years results from the SPARK open-label, multicentre, randomized phase IIIb trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13023-017-0600-x |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13023-017-0600-x |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180828 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 132278626 |a Gramer, Gwendolyn |m 132278626:Gramer, Gwendolyn |d 910000 |d 910500 |e 910000PG132278626 |e 910500PG132278626 |k 0/910000/ |k 1/910000/910500/ |p 11 | ||
| 999 | |a KXP-PPN1580453279 |e 302405605X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"9 March 2017"}],"id":{"eki":["1580453279"],"doi":["10.1186/s13023-017-0600-x"]},"name":{"displayForm":["Ania C. Muntau, Alberto Burlina, François Eyskens, Peter Freisinger, Corinne De Laet, Vincenzo Leuzzi, Frank Rutsch, H. Serap Sivri, Suresh Vijay, Milva Orquidea Bal, Gwendolyn Gramer, Renata Pazdírková, Maureen Cleary, Amelie S. Lotz-Havla, Alain Munafo, Diane R. Mould, Flavie Moreau-Stucker and Daniela Rogoff"]},"physDesc":[{"extent":"11 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2006-","publisher":"BioMed Central","dateIssuedKey":"2006","publisherPlace":"London"}],"id":{"issn":["1750-1172"],"eki":["50900637X"],"zdb":["2225857-7"]},"pubHistory":["1.2006 -"],"part":{"pages":"1-11","year":"2017","extent":"11","text":"12(2017), Artikel-ID 47, Seite 1-11","volume":"12"},"note":["Gesehen am 01.09.10"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years results from the SPARK open-label, multicentre, randomized phase IIIb trialOrphanet journal of rare diseases","language":["eng"],"recId":"50900637X","title":[{"subtitle":"OJRD","title":"Orphanet journal of rare diseases","title_sort":"Orphanet journal of rare diseases"}]}],"title":[{"title_sort":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years","title":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years","subtitle":"results from the SPARK open-label, multicentre, randomized phase IIIb trial"}],"person":[{"display":"Muntau, Ania","roleDisplay":"VerfasserIn","role":"aut","family":"Muntau","given":"Ania"},{"roleDisplay":"VerfasserIn","display":"Gramer, Gwendolyn","role":"aut","family":"Gramer","given":"Gwendolyn"}],"note":["Gesehen am 28.08.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1580453279"} | ||
| SRT | |a MUNTAUANIAEFFICACYSA9201 | ||